HEALTH TECHNOLOGY

Health Care Software Provider GoMeyra Announces Partnership with Visit Healthcare

GoMeyra | July 20, 2022 | Read time : 59:11 min

Health Care

GoMeyra, a cloud software company dedicated to providing innovative, real-time software for the health care industry, announces partnership with Visit Healthcare, a nationwide turnkey mobile medical provider. GoMeyra’s laboratory information management system (LIMS) will now power the health care company’s onsite lab diagnostic testing, immunizations and other medical solutions for enterprise-level clients.

Our need for a reliable technology partner has increased tremendously in the past few years, and the portals we have been using have limited flexibility, especially as we move into mobile medical services beyond COVID. GoMeyra has already bolstered our mobile capabilities with its versatile technology that has the ability to customize to our clients’ changing needs. Their team is quick to respond and the reporting process is simple. We also work with many of the same clients, so the transition to a new system has been easy. They are a great match for us”

 Visit Healthcare CEO, Olympia Bliss

GoMeyra’s Laboratory Information Management Solution is a revolutionary, cloud-based software platform solution that empowers labs, health care facilities and medical practices to achieve unprecedented processing times for COVID-19 RT-PCR, rapid PCR, antigen, antibody and serology testing while automating procedures and managing samples faster and more accurately. New testing panels will be added in the very near future.

“Visit Healthcare is growing fast, and like many growing companies, they need technology to be more agile and evolve with their business. Many companies, when they start out, don’t realize how important this flexibility is until they outgrow their current system. We offer medical practitioners a painless transition and peace of mind so they can focus on operations and not worry about their technology needs,” added GoMeyra Founder and Chief Executive Officer, Jaswant S. Tony.

Visit Healthcare will also have access to GoVirtual Clinic, GoMeyra’s newly launched telehealth platform, which is fully integrated with GoMeyra LIMS. GoVirtual Clinic is a next-generation platform that includes a suite of solutions for medical professionals to conduct virtual patient appointments while comprehensively managing patient care and related electronic health records. The first phase of the platform features ways to seamlessly schedule and manage virtual testing appointments, order test kits, monitor online waiting rooms, conduct virtual appointments, and share test results with patients in real-time. For product demonstrations, contact info@GoMeyra.com or call (844) 203-3960.

About GoMeyra
GoMeyra is a trusted technology partner providing innovative, real-time software solutions that simplifies processes and delivers unparalleled customer service for the health care industry. GoMeyra’s premiere product, GoMeyra LIMS, is an automated, customizable laboratory information management system that improves workflow efficiencies, enabling laboratories, medical providers, employers and enterprise organizations to process lab tests and deliver patient results with unprecedented speed. GoMeyra Network, a unique built-in feature, allows independent labs across the country to collaborate and compete with larger diagnostic providers.

About Visit Healthcare
Visit Healthcare, a nationwide turnkey mobile medical provider, works with states, counties, government agencies, schools, and private industry on rapid response healthcare solutions. With a background in emergency response, Visit Healthcare has a proven ability to mobilize health care workers across the country in a very short period of time and currently operates testing and/or vaccination services in more than 26 states. With healthcare professionals and numerous CLIA-certified high-complexity laboratories at the ready, Visit Healthcare plays an active role in additional health care services including flu​ clinics, telehealth, and molecular testing beyond COVID-19. 

Spotlight

The healthcare industry will continue to evolve, and it’s more important than ever to put the needs of the patient first. As patient payment liability continues to grow through HDHPs and state and federal insurance marketplaces, providers must develop new ways to collect for services rendered.  With the advent of healthcare consumerism and the growing trend towards clinical and financial transparency, patients have more control over how their care is administered and paid.

Spotlight

The healthcare industry will continue to evolve, and it’s more important than ever to put the needs of the patient first. As patient payment liability continues to grow through HDHPs and state and federal insurance marketplaces, providers must develop new ways to collect for services rendered.  With the advent of healthcare consumerism and the growing trend towards clinical and financial transparency, patients have more control over how their care is administered and paid.

Related News

HEALTHTECH SECURITY,FUTURE OF HEALTHCARE

Sightpath Medical Acquires Accusite Surgical

Sightpath Medical | November 22, 2022

Sightpath Medical, the leading provider of mobile ophthalmic services for cataract and refractive surgery, announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Founded in 1991, Sightpath Medical delivers custom access to advanced ophthalmic equipment, instruments, and services to facilities and surgeons across the United States. Through its patented technology, the company was the first to mobilize phacoemulsification machines, excimer lasers, the IntraLase Femtosecond Laser, and the LenSx Femtosecond Laser. Sightpath Medical has earned the trust of medical professionals and patients nationwide through the quality of its equipment, the skill of its employees, and the dedication and responsiveness of its staff. Accusite Surgical is a mobile cataract surgical company that outsources state-of-the-art equipment, technology, and certified staff to surgeons, ambulatory surgical centers, and hospitals. For over 28 years, the company has assisted in more than 200,000 procedures throughout the Southeastern U.S. In connection with the transaction, D. Lynn Godfrey, Founder and Chief Executive Officer of Accusite Surgical, will join Sightpath Medical as Chief Strategy Officer. “This strategic combination bolsters Sightpath Medical’s market-leading position and enhances our ability to deliver variable, tailored access to the expert personnel, equipment, and supplies surgeons need to provide critical eye care. We are delighted to begin integrating the Accusite Surgical business into ours and are equally excited to welcome Lynn Godfrey, who is an experienced and creative executive, to our management team. We look forward to growing Sightpath Medical together.” Joel Gaslin, President and CEO of Sightpath Medical Mr. Godfrey added, “After 28 years, I began exploring the long-term options for my business and quickly determined that the Sightpath Medical executive team and its financial partner, MGG Investment Group, were the right partners for Accusite Surgical. We are closely aligned on our core mission of helping surgeons and their referring Optometrists provide patients with excellent eye care and, ultimately, better vision. I am thrilled to commence Accusite Surgical’s next chapter as part of Sightpath Medical.” About Sightpath Medical Sightpath Medical is the leading U.S. provider of mobile ophthalmic services for cataract, refractive and laser-assisted surgery. Working alongside more than 1,200 surgeons and the staffs of their surgical facilities for more than 30 years, Sightpath Medical is the market-leading choice for surgeons, ASCs, and hospitals due to our proven ability to deliver the staff, equipment, and supplies wherever and whenever they are needed – regardless of geography. About Accusite Surgical For nearly three decades, Accusite Surgical has been a leading provider of state-of-the-art equipment, supplies, and support for cataract surgery in the Southeastern United States. Accusite Surgical is a trusted partner to ASCs and hospitals and ophthalmologists for cataract surgery services and is committed to helping surgeons grow their practices while delivering superior outcomes for patients.

Read More

HEALTH TECHNOLOGY

WELL Health to Acquire EMR, Billing and Clinical Assets from CloudMD

WELL Health Technologies Corp. | October 12, 2022

WELL Health Technologies Corp. a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce it has entered into an agreement to acquire Cloud Practice Inc. and three clinics from CloudMD Software & Services Inc. "This transaction demonstrates our dedication to expanding and strengthening WELL's Canadian healthcare offering through disciplined capital allocation. This acquisition will also enable our EMR and billing divisions to enter new markets in the Canadian Prairies where we look forward to supporting healthcare practitioners' access to new digital health innovations." Hamed Shahbazi, CEO and Founder of WELL Cloud Practice is a medical software application company with products including Juno EMR, a cloud based EMR solution based on OSCAR1, and ClinicAid, a medical billing software used by healthcare practitioners who don't need access to a full EMR. Outside of WELL who is the largest provider of OSCAR1 EMR products and services, Juno EMR represented the largest remaining asset and market share available in the OSCAR1 based EMR industry. Both Juno EMR and ClinicAid represent WELL's entrance into the Alberta and Saskatchewan markets for its EMR and medical billing related lines of business. Both assets will be integrated into WELL's Provider Solutions Business Unit, under WELL's existing EMR and Billing platforms. Amir Javidan, COO of WELL commented, "This transaction is a win for healthcare practitioners and their patients as it will allow software users and clinicians joining our network to have access to WELL's innovative Apps.Health platform which includes dozens of apps designed by leading 3rd party digital health companies providing advanced physician tools such as an AI-powered virtual assistant to premium digital patient engagement tools that can drive significant operating efficiencies for clinics." The three primary care clinics being acquired in the Transaction currently have a total staff of 20 physicians operating out of two clinics in Vancouver, BC and one clinic in Surrey, BC. These clinics are owned by subsidiaries of CloudMD, with all of the shares of these entities being acquired as part of the Transaction. These three clinics will be integrated into WELL's existing primary care clinic network under WELL Health Canada Clinics Inc. About WELL Health Technologies Corp. WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on OTCQX under the symbol "WHTCF".

Read More

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More